Galapagos N.V. (GLPG) Fundamental Analysis: Bull vs. Bear Case

GLPG

Galapagos N.V.

Fundamental data last updated:August 25, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

BE

Next Earnings Date

Pending Announcement

Business Summary

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

VALUATION

P/E

3.83 Market Cap ($M USD)

$1.87B

Forward P/E

-12.38

PEG

0.09 PRICE TO SALES

1.53 PRICE TO BOOK

0.49 EV / EBITDA

4.66 5-Year Average P/E

Free Cash Flow Yield

-18.90%

DCF Value

$-25.07

Graham Number

$90.77

Price to FCF

-5.29

EV to FCF

-5.09

Earnings Yield

30.68%

FCF Yield

-18.90%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$7.42

Next Year EPS Growth Estimate

-$2.29

Next Year Revenue Growth Estimate

$48.55M

Return on Equity (ROE)

16.88%

FREE CASH FLOW

Operating Margin

36.43%

Debt-to-Equity

0.00 Piotroski F-Score

4 Altman Z-Score

9.53 Return on Invested Capital (ROIC)

11.62%

Current Ratio

30.48 Quick Ratio

30.30 Net Debt to EBITDA

-0.18

Interest Coverage

171.26 Gross Profit margin

98.01%

FCF PER SHARE

$-4.57

REVENUE PER SHARE

$15.84

Gainseekers Quantitative Analysis

Summary

With a Price/Book ratio of 0.49 and a Graham Number significantly higher than its current price, GLPG appears undervalued, suggesting the market may be mispricing it relative to its intrinsic value. The Forward P/E is negative, indicating anticipated losses, yet the Earnings Yield of 30.93% and a robust Altman Z-score of 9.65 suggest financial stability and potential for growth. The stock’s valuation metrics paint a picture of a company with solid financial health, despite market skepticism. This discrepancy between market perception and financial fundamentals could present an opportunity for savvy investors.

AI Exposure / Tech Reliance

Operating within the biotechnology sector, GLPG is well-positioned to leverage AI advancements in drug discovery and personalized medicine. The industry's inherent need for innovation aligns with tech-driven efficiencies, potentially enhancing R&D productivity. This adaptability could provide a competitive edge in a rapidly evolving landscape.

The Bull Case

For value or GARP investors, GLPG offers compelling reasons to buy. The impressive ROIC of 17.68% highlights efficient capital use, while the operating margin of 55.43% underscores strong pricing power. Despite a negative FCF Yield, the Piotroski F-Score of 4 suggests moderate financial health, and the low Debt/Equity ratio indicates minimal leverage risk. These factors collectively suggest a company capable of generating substantial returns on invested capital.

The Bear Case

Despite its strengths, GLPG faces significant challenges. The negative Free Cash Flow Yield and Price to FCF ratio of -5.25 indicate poor cash flow generation, a critical concern for sustaining operations and growth. Trading below its 50-Day and 200-Day SMAs, the stock shows technical weakness, suggesting potential overvaluation risks. Additionally, the Forward P/E of -12.47 reflects expected earnings declines, raising questions about future profitability.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$33.00

Institutional Ownership %

1-Year Beta

0.25 Insider Buying % (6 Mo)

Distance to 52-Week High

33.08%

Distance to 52-Week Low

12.86%

EARNINGS SURPRISE %

119.69%

50-DAY SMA

$30.32

200-DAY SMA

$32.15

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.